Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CRIS Stock Forecast 2026-2027
$4.63
Current Price
$9.22M
Market Cap
Buy 4
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to CRIS Price Targets
+8,539.3%
To High Target of $400.00
+7,243.4%
To Median Target of $340.00
+2,059.8%
To Low Target of $100.00
CRIS Price Momentum
-6.7%
1 Week Change
+1,002.4%
1 Month Change
+157.2%
1 Year Change
+367.7%
Year-to-Date Change
-31.3%
From 52W High of $6.74
+2,472.2%
From 52W Low of $0.18
📊 TOP ANALYST CALLS
Did CRIS Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Curis is one of their latest high-conviction picks.
Latest CRIS Stock Price Targets & Analyst Predictions
Based on our analysis of 8 Wall Street analysts, CRIS has a bullish consensus with a median price target of $340.00 (ranging from $100.00 to $400.00). The overall analyst rating is Strong Buy (9.5/10). Currently trading at $4.63, the median forecast implies a 7,243.4% upside. This outlook is supported by 4 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CRIS Analyst Ratings
4
Buy
0
Hold
0
Sell
CRIS Price Target Range
Low
$100.00
Average
$340.00
High
$400.00
Current: $4.63
Latest CRIS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CRIS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 20, 2026 | HC Wainwright & Co. | Sara Nik | Buy | Reiterates | $17.00 |
| May 19, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Assumes | $17.00 |
| Mar 31, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Dec 10, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Nov 15, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Nov 1, 2024 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Sep 27, 2024 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $26.00 |
| Aug 1, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| May 15, 2024 | Truist Securities | Buy | Maintains | $N/A | |
| May 15, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| May 15, 2024 | Cantor Fitzgerald | Overweight | Reiterates | $N/A | |
| May 8, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Feb 9, 2024 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Nov 17, 2023 | Truist Securities | Buy | Initiates | $N/A | |
| Sep 29, 2023 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $51.00 |
| Sep 25, 2023 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $6.00 |
| Sep 7, 2023 | Cantor Fitzgerald | Alethia Young | Overweight | Reiterates | $3.00 |
| Aug 4, 2023 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $6.00 |
| Jul 11, 2023 | Cantor Fitzgerald | Alethia Young | Overweight | Reiterates | $3.00 |
| Jul 7, 2023 | HC Wainwright & Co. | Edward White | Buy | Maintains | $6.00 |
Curis Inc. (CRIS) Competitors
The following stocks are similar to Curis based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Curis Inc. (CRIS) Financial Data
Curis Inc. has a market capitalization of $9.22M with a P/E ratio of -0.4x. The company generates $7.06M in trailing twelve-month revenue with a -299.7% profit margin.
Revenue growth is -100.0% quarter-over-quarter, while maintaining an operating margin of -485.1% and return on equity of -693.9%.
Valuation Metrics
Market Cap
$9.22M
Enterprise Value
$-4,406,559
P/E Ratio
-0.4x
PEG Ratio
0.0x
Price/Sales
1.4x
Growth & Margins
Revenue Growth (YoY)
-100.0%
Gross Margin
N/A
Operating Margin
-485.1%
Net Margin
-299.7%
EPS Growth
-100.0%
Financial Health
Cash/Price Ratio
+166.2%
Current Ratio
1.1x
Debt/Equity
10.5x
ROE
-693.9%
ROA
-62.1%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Curis Inc. (CRIS) Business Model
About Curis Inc.
What They Do
Develops drug candidates for human cancers.
Business Model
Curis Inc. operates as a biotechnology company focused on developing innovative drug candidates for cancer treatment. The company generates revenue through clinical collaborations, licensing agreements, and potential market sales of its drug candidates, particularly emavusertib, which targets specific cancer pathways.
Additional Information
Curis is based in Lexington, Massachusetts, and has received Orphan Drug Designation for emavusertib, indicating its potential in treating rare blood cancers. The company aims to enhance treatment efficacy by combining its therapies with existing cancer treatments and is actively pursuing multiple indications in hematologic malignancies.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
20
CEO
Mr. James E. Dentzer
Country
United States
IPO Year
2000
Website
www.curis.comCuris Inc. (CRIS) Latest News & Analysis
Latest News
Quick Summary
Curis, Inc. (NASDAQ: CRIS) has reached a significant enrollment milestone in its TakeAim CLL study for emavusertib (CA-4948), an IRAK4 and FLT3 inhibitor.
Why It Matters
Curis, Inc. achieving a key enrollment milestone in its TakeAim CLL study may indicate progress in drug development, potentially impacting stock performance and market confidence.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Curis, Inc. has opened 11 sites for patient enrollment in its Phase 2 TakeAim CLL study of emavusertib with zanubrutinib. Initial dosing is expected by July 2026, with data due December 2026.
Why It Matters
The initiation of patient enrollment in a key clinical study and reaffirmation of dosing timelines signal progress for Curis, potentially influencing stock performance and investor confidence.
Source: PRNewsWire
Market Sentiment:
Neutral
Curis, Inc. (CRIS) Q1 2026 Earnings Call Transcript
2 months ago
Quick Summary
Curis, Inc. (CRIS) held its Q1 2026 earnings call, discussing financial performance and strategic updates. Further details on revenues and guidance may be available in the full transcript.
Why It Matters
Curis, Inc.'s Q1 2026 earnings call provides critical insights into the company's financial health, performance metrics, and future outlook, influencing investment decisions and stock valuation.
Source: Seeking Alpha
Market Sentiment:
Neutral
Curis Provides First Quarter 2026 Business Update
2 months ago
Quick Summary
Management will hold a conference call today at 4:30 p.m. ET.
Why It Matters
The management's conference call may provide insights into company performance, strategies, or financial guidance, potentially influencing stock price and investor sentiment.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Curis, Inc. (NASDAQ: CRIS) will release its Q1 2026 financial and operational results on May 12, 2026, at 4:00 p.m. The company focuses on the IRAK4 and FLT3 inhibitor, emavusertib.
Why It Matters
Curis, Inc.'s upcoming financial results release may impact stock performance, reflecting investor sentiment towards its drug development progress and financial health.
Source: PRNewsWire
Market Sentiment:
Neutral
Kiniksa Pharmaceuticals International, plc (KNSA) Tops Q1 Earnings and Revenue Estimates
2 months ago
Quick Summary
Kiniksa Pharmaceuticals (KNSA) reported Q3 earnings of $0.27 per share, surpassing estimates of $0.18 and increasing from $0.11 per share year-over-year.
Why It Matters
Kiniksa Pharmaceuticals' earnings beat expectations, signaling strong performance and growth, which can boost investor confidence and potentially increase stock value.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About CRIS Stock
What is Curis Inc.'s (CRIS) stock forecast for 2027?
Based on our analysis of 8 Wall Street analysts, Curis Inc. (CRIS) has a median price target of $340.00. The highest price target is $400.00 and the lowest is $100.00.
Is CRIS stock a good investment in 2027?
According to current analyst ratings, CRIS has 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $4.63. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CRIS stock?
Wall Street analysts predict CRIS stock could reach $340.00 in the next 12 months. This represents a 7,243.4% increase from the current price of $4.63. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Curis Inc.'s business model?
Curis Inc. operates as a biotechnology company focused on developing innovative drug candidates for cancer treatment. The company generates revenue through clinical collaborations, licensing agreements, and potential market sales of its drug candidates, particularly emavusertib, which targets specific cancer pathways.
What is the highest forecasted price for CRIS Curis Inc.?
The highest price target for CRIS is $400.00 from at , which represents a 8,539.3% increase from the current price of $4.63.
What is the lowest forecasted price for CRIS Curis Inc.?
The lowest price target for CRIS is $100.00 from at , which represents a 2,059.8% increase from the current price of $4.63.
What is the overall CRIS consensus from analysts for Curis Inc.?
The overall analyst consensus for CRIS is bullish. Out of 8 Wall Street analysts, 4 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $340.00.
How accurate are CRIS stock price projections?
Stock price projections, including those for Curis Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 18, 2026 2:18 AM UTC